clinical efficacy of oxaliplatin-based systemic chemotherapy in treating advanced hepatocellular carcinoma: a comparative study of two regimens
Clicks: 177
ID: 172140
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
177 views
20 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #49 of 78 articles by views in lontar komputer
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
ObjectiveTo evaluate the therapeutic efficacy and toxicity of oxaliplatin (OXA)-based systemic chemotherapy in patients with advanced hepatocellular carcinoma (HCC). MethodsThirty patients with advanced HCC admitted to our hospital from June 2009 to June 2013 were randomly divided into CapeOX group (15 patients, treated with OXA and capecitabine or CAP) and FOLFOX group (15 patients, treated with OXA and calcium folinate or CF, followed by fluorouracil or 5-FU). The therapeutic effects were evaluated after two cycles of treatment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Assessment criteria included overall response rate (OR), time to tumor progression (TTP), and overall survival (OS) analyzed by Kaplan-Meier survival curves, as well as the toxicity profile of the combination chemotherapy. Comparison of OR was made by chi-square test; assessment of tumor response and toxicity profile was performed by Mann-Whitney U test; OS and TTP were analyzed by log-rank test. ResultsIn the CapeOX group, the OR was 133%, and the mean OS and TTP were 10.4 months and 5.0 months, respectively. In the FOLFOX group, the OR was 6.7%, and the mean OS and TTP were 9.0 months and 4.7 months, respectively. The differences between the two groups had no statistical significance in all three parameters (P=0.543, 0.606, and 0.769, respectively). Compared with the FOLFOX group, the CapeOX group had significantly lower toxicity rates in gastrointestinal tract and myelosuppression (P=0.006 and 0.002, respectively). ConclusionsThe OXA-based systemic chemotherapy shows anti-tumor effects for advanced HCC, and there is no significant difference in efficacy between the two regimens. Decisions regarding the choice of specific treatment should be based on the patients' clinical conditions.
| Reference Key |
xiaowen2014linchuangclinical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;CHEN Xiaowen |
| Journal | lontar komputer |
| Year | 2014 |
| DOI |
10.3969/j.issn.1001-5256.2014.12.025
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.